SoftMedx Completes Follow-Up Review, Confirms Fulfilment of All Resumption Conditions

Bulletin Express07-03

SoftMedx Healthcare Limited (SoftMedx) announced that all resumption conditions required by Hong Kong Exchanges and Clearing Limited for reinstating trading in its shares have been met as of 2 July 2026.

The resumption framework comprised three key conditions:

1. Publication of the original resumption announcement dated 31 October 2025. 2. Engagement of an independent compliance (IC) consultant to conduct a follow-up review on 30 September 2025 and submit a corresponding report to both SoftMedx and the Securities and Futures Commission. 3. Public disclosure of the follow-up review results.

According to the latest filing, the IC Consultant has verified that every recommendation outlined in the earlier IC Report has been fully implemented, with “no exception noted.” Consequently, SoftMedx confirms that Conditions 2 and 3 have now been satisfied, completing the entire resumption checklist.

Corporate Governance Update As at 2 July 2026, the board of SoftMedx consists of one executive director, Mr. Lin Pinzhuo, and three independent non-executive directors, Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing. The announcement was authorized for release by Company Secretary Mr. Lam Sung Him Gaston.

The fulfilment of these procedural requirements positions SoftMedx for trading resumption on The Stock Exchange of Hong Kong, subject to the exchange’s final confirmation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115356770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115356770","market":"us","top_or_hot":-1,"title":"SoftMedx Completes Follow-Up Review, Confirms Fulfilment of All Resumption Conditions","media":"Bulletin Express","content":"<p>SoftMedx Healthcare Limited (SoftMedx) announced that all resumption conditions required by Hong Kong Exchanges and Clearing Limited for reinstating trading in its shares have been met as of 2 July 2026.</p>\n<p>The resumption framework comprised three key conditions:</p>\n<p>1. Publication of the original resumption announcement dated 31 October 2025.  \n2. Engagement of an independent compliance (IC) consultant to conduct a follow-up review on 30 September 2025 and submit a corresponding report to both SoftMedx and the Securities and Futures Commission.  \n3. Public disclosure of the follow-up review results.</p>\n<p>According to the latest filing, the IC Consultant has verified that every recommendation outlined in the earlier IC Report has been fully implemented, with “no exception noted.” Consequently, SoftMedx confirms that Conditions 2 and 3 have now been satisfied, completing the entire resumption checklist.</p>\n<p>Corporate Governance Update  \nAs at 2 July 2026, the board of SoftMedx consists of one executive director, Mr. Lin Pinzhuo, and three independent non-executive directors, Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing. The announcement was authorized for release by Company Secretary Mr. Lam Sung Him Gaston.</p>\n<p>The fulfilment of these procedural requirements positions SoftMedx for trading resumption on The Stock Exchange of Hong Kong, subject to the exchange’s final confirmation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SoftMedx Completes Follow-Up Review, Confirms Fulfilment of All Resumption Conditions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoftMedx Completes Follow-Up Review, Confirms Fulfilment of All Resumption Conditions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 06:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SoftMedx Healthcare Limited (SoftMedx) announced that all resumption conditions required by Hong Kong Exchanges and Clearing Limited for reinstating trading in its shares have been met as of 2 July 2026.</p>\n<p>The resumption framework comprised three key conditions:</p>\n<p>1. Publication of the original resumption announcement dated 31 October 2025.  \n2. Engagement of an independent compliance (IC) consultant to conduct a follow-up review on 30 September 2025 and submit a corresponding report to both SoftMedx and the Securities and Futures Commission.  \n3. Public disclosure of the follow-up review results.</p>\n<p>According to the latest filing, the IC Consultant has verified that every recommendation outlined in the earlier IC Report has been fully implemented, with “no exception noted.” Consequently, SoftMedx confirms that Conditions 2 and 3 have now been satisfied, completing the entire resumption checklist.</p>\n<p>Corporate Governance Update  \nAs at 2 July 2026, the board of SoftMedx consists of one executive director, Mr. Lin Pinzhuo, and three independent non-executive directors, Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing. The announcement was authorized for release by Company Secretary Mr. Lam Sung Him Gaston.</p>\n<p>The fulfilment of these procedural requirements positions SoftMedx for trading resumption on The Stock Exchange of Hong Kong, subject to the exchange’s final confirmation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00648","symbol_name":"京玖康疗","start_time":0,"source_url":"","article_id":"1115356770","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115356770","pubTimestamp":1783031074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SoftMedx Healthcare Limited (SoftMedx) announced that all resumption conditions required by Hong Kong Exchanges and Clearing Limited for reinstating trading in its shares have been met as of 2 July...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00648":"京玖康疗"},"translate_title":"SoftMedx完成随访审查，确认满足所有恢复条件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00648":1},"content_text":"SoftMedx Healthcare Limited (SoftMedx) announced that all resumption conditions required by Hong Kong Exchanges and Clearing Limited for reinstating trading in its shares have been met as of 2 July 2026.\nThe resumption framework comprised three key conditions:\n1. Publication of the original resumption announcement dated 31 October 2025.  \n2. Engagement of an independent compliance (IC) consultant to conduct a follow-up review on 30 September 2025 and submit a corresponding report to both SoftMedx and the Securities and Futures Commission.  \n3. Public disclosure of the follow-up review results.\nAccording to the latest filing, the IC Consultant has verified that every recommendation outlined in the earlier IC Report has been fully implemented, with “no exception noted.” Consequently, SoftMedx confirms that Conditions 2 and 3 have now been satisfied, completing the entire resumption checklist.\nCorporate Governance Update  \nAs at 2 July 2026, the board of SoftMedx consists of one executive director, Mr. Lin Pinzhuo, and three independent non-executive directors, Mr. Ngok Ho Wai, Ms. Tang Cuihuen and Mr. Yiu Chun Wing. The announcement was authorized for release by Company Secretary Mr. Lam Sung Him Gaston.\nThe fulfilment of these procedural requirements positions SoftMedx for trading resumption on The Stock Exchange of Hong Kong, subject to the exchange’s final confirmation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115356770","isCrawlerRequest":true}